MX2023005864A - Agente dirigido al receptor 2 del factor de crecimiento epidermico humano (her2). - Google Patents

Agente dirigido al receptor 2 del factor de crecimiento epidermico humano (her2).

Info

Publication number
MX2023005864A
MX2023005864A MX2023005864A MX2023005864A MX2023005864A MX 2023005864 A MX2023005864 A MX 2023005864A MX 2023005864 A MX2023005864 A MX 2023005864A MX 2023005864 A MX2023005864 A MX 2023005864A MX 2023005864 A MX2023005864 A MX 2023005864A
Authority
MX
Mexico
Prior art keywords
targeting agent
her2
her2 targeting
fragment
antigen
Prior art date
Application number
MX2023005864A
Other languages
English (en)
Spanish (es)
Inventor
Yukinari Kato
Mika Kaneko
Daisuke Nakayama
Masayuki KUROGI
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of MX2023005864A publication Critical patent/MX2023005864A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57415Specifically defined cancers of breast
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
MX2023005864A 2020-11-30 2021-11-29 Agente dirigido al receptor 2 del factor de crecimiento epidermico humano (her2). MX2023005864A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020198044 2020-11-30
JP2021110912 2021-07-02
PCT/JP2021/043538 WO2022114163A1 (ja) 2020-11-30 2021-11-29 Her2標的化剤

Publications (1)

Publication Number Publication Date
MX2023005864A true MX2023005864A (es) 2023-06-05

Family

ID=81754499

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005864A MX2023005864A (es) 2020-11-30 2021-11-29 Agente dirigido al receptor 2 del factor de crecimiento epidermico humano (her2).

Country Status (10)

Country Link
US (2) US20240002531A1 (enExample)
EP (1) EP4253420A4 (enExample)
JP (2) JP7393774B2 (enExample)
KR (1) KR20230114747A (enExample)
AU (1) AU2021387127A1 (enExample)
CA (1) CA3199473A1 (enExample)
IL (1) IL303154A (enExample)
MX (1) MX2023005864A (enExample)
TW (1) TW202229359A (enExample)
WO (1) WO2022114163A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118871471A (zh) 2022-04-08 2024-10-29 菲特治疗公司 用于肿瘤靶向的嵌合抗原受体
AU2023249802A1 (en) * 2022-04-08 2024-10-24 Fate Therapeutics, Inc. Cells having solid tumor targeting backbone and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA013563B1 (ru) 2000-10-06 2010-06-30 Киова Хакко Кирин Ко., Лтд. Трансгенное животное, продуцирующее антитела с измененными углеводными цепями, способ получения антител и содержащее антитела лекарственное средство
SI2330131T1 (sl) 2009-12-07 2015-02-27 Fundacio Privada Institucio Catalana De Recerca I Estudis Avancants Protitelesa proti HER2 skrajšani varianti CTF-611
WO2012047427A2 (en) * 2010-08-31 2012-04-12 The Regents Of The University Of California Antibodies for botulinum neurotoxins
WO2019246021A1 (en) * 2018-06-18 2019-12-26 Dxdiscovery, Inc. Methods and compositions for pertussis diagnosis
CN118871471A (zh) * 2022-04-08 2024-10-29 菲特治疗公司 用于肿瘤靶向的嵌合抗原受体

Also Published As

Publication number Publication date
JPWO2022114163A1 (enExample) 2022-06-02
TW202229359A (zh) 2022-08-01
US20240002531A1 (en) 2024-01-04
WO2022114163A1 (ja) 2022-06-02
EP4253420A1 (en) 2023-10-04
JP2024020436A (ja) 2024-02-14
KR20230114747A (ko) 2023-08-01
EP4253420A4 (en) 2024-11-06
AU2021387127A1 (en) 2023-06-22
IL303154A (en) 2023-07-01
US11981747B1 (en) 2024-05-14
CA3199473A1 (en) 2022-06-02
JP7393774B2 (ja) 2023-12-07

Similar Documents

Publication Publication Date Title
WO2020236817A3 (en) Mcl-1 inhibitor antibody-drug conjugates and methods of use
WO2021227307A8 (zh) 抗cd73抗体及其用途
MY205758A (en) Anti-nkg2a antibodies and uses thereof
MX2024013016A (es) Anticuerpos anti-pd1 para usarse en el tratamiento del cancer
PH12019501330A1 (en) Antibody drug conjugates for ablating hematopoietic stem cells
MX2014001373A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
MX348581B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
WO2021090062A8 (en) Anti-mesothelin eribulin antibody-drug conjugates and methods of use
MX2019013753A (es) Combinaciones de inmunoconjugados anti-folr1 y anticuerpo anti-pd-1.
MX2021010453A (es) Conjugados anticuerpo-farmaco que comprenden anticuerpos contra dlk1 humana y uso de estos.
AU2020212767A8 (en) Combined pharmaceutical composition for treating tumor
WO2022034524A3 (en) Antibodies against ilt2 and use thereof
MX2023005864A (es) Agente dirigido al receptor 2 del factor de crecimiento epidermico humano (her2).
WO2021207433A3 (en) Epitopes of sars-cov-2 neutralizing antibodies
MY209791A (en) Anti-cd79b antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
ZA202308896B (en) Antibodies binding trop2 and uses thereof
MX2025001452A (es) Anticuerpos anti-ccr8 y metodos de uso
ZA202408388B (en) Antibodies targeting sirp-alpha and uses thereof
MX2023013726A (es) Anticuerpos multiespecificos anti-cea y anti-cd137 y metodos de uso.
UY38265A (es) Conjugados anticuerpo droga para ablación de células madre hematopoyéticas
IL242791B (en) Antibodies against the toxin ricin
MX2025004751A (es) Anticuerpos anti molecula de adhesion celular l1 (l1-cam) y sus usos para aplicaciones diagnosticas y terapeuticas
MX2025001042A (es) Formulaciones de anticuerpos contra tl1a
WO2020033926A3 (en) Antibodies that bind cd277 and uses thereof